FACE is proud to be of the first in the world to offer CELLFINA™- The first FDA-cleared technology to get to the structural cause of cellulite, in one treatment, and lasts minimum two years. Cellfina™ also has a 96% satisfaction rate in year two! FACE has teamed up with Dermatologist Dr. Chris Remishofsky, to further your treatment options for Cellfina in Michigan. This breakthrough technology is in a class of its own and is at the forefront of results beyond even surgical methods.
We complement Cellfina™ with other non-invasive options for tightening and permanent fat reduction. Call FACE for your consultation today at 248-663-0161!
Q. What is Cellfina™?
A. Cellfina™ is the only FDA-cleared minimally invasive, one-time procedure clinically proven to improve the appearance of cellulite for at least two years—the longest FDA-cleared duration for a cellulite treatment. A straightforward solution to cellulite, Cellfina™, combines a proven approach with innovative, proprietary technology, to produce precise, long-lasting results.
Q. What areas does Cellfina™ treat?
A. Cellfina is FDA-cleared to treat the buttocks, back of thighs, sides of thighs, and front of thighs.
Q. How does the Cellfina™ System work?
A. The Cellfina™ System treats the primary structural cause of cellulite—the connective bands woven throughout fat in the thighs and buttocks. These tight bands pull down the skin, creating the puckering you see on the surface of the skin. Similar to a rubber band under tension, once released, the treated skin bounces back to smooth itself out.
Q. How long do results from Cellfina™ last?
A. Patients in the pivotal study showed significant improvement shortly after the treatment, with results lasting at least two years— the longest FDA clearance for a cellulite treatment.
Q. How soon will I see improvements with Cellfina™?
A. Results can be seen in as little as three days. In the pivotal study, patient satisfaction was 85 percent at three months, 94 percent at one year and 96 percent at two years, surpassing the patient satisfaction rates of other leading cellulite treatments.
Q. How does Cellfina™ compare with other non-invasive and energy-based procedures for cellulite?
A. Other technologies that are completely noninvasive are wonderful and used complimentary to Cellfina to additionally tighten, smooth, build collagen, and create lipolysis (shrink the fat cells). One such device that is voted #1 by consumers that FACE was the first to have in Michigan is Venus SculptFX. Other devices, like Vanquish, are used to permanently destroy fat cells without pain or downtime.
Q. Does Cellfina™ involve cutting?
A. Cellfina does not involve an operating room or general anesthesia. It relies on a minimally invasive, tiny needle-sized device to treat the cellulite-causing bands just below the surface of the skin.
Q. How does Cellfina™ compare with Cellulaze?
A. Cellulaze is a surgical laser-assisted procedure that doesn’t get to the structural part of cellulite, getting rid of the bands, and has more side effects, and doesn’t come close to the results of Cellfina, and Cellfina is not a surgical procedure. Cellulaze can also take several months and more to see the skin changes, whereas Cellfina results are within days to weeks, and progressively get better. Also, Cellfina is the only FDA-cleared procedure to last minimum two years and has a 96% satisfaction rate.
Q. Are there any side effects with Cellfina™?
A. No serious adverse events were associated with Cellfina™. The FDA‐cleared pivotal study was soreness, tenderness, and bruising. Just three days after treatment, patients rated their pain as minimal (2.7 on a scale of 0 to 10; 0=no pain, 10=extreme pain) and most (82 percent) felt pain only with touch or pressure to the area treated. This minimal pain improved quickly with time. More than 90 percent of patients had no bruising at four weeks.
Q. Will I need to take time off?
A. There is limited downtime associated with Cellfina™ . Some patients experience initial soreness and tenderness, but these side effects resolve rapidly with time.